Mankind Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd today inked a sub-licensing agreement to co-market anti-diabetes drug remogliflozin etabonate in India.
Under the agreement, Mankind Pharma will market Remogliflozin under its own trademark while Glenmark will manufacture and supply the drug to the company, Delhi-based Mankind Pharma said in a release.
Mankind Pharma did not give details on the brand under which it will launch the medicine.
“Remogliflozin is 50% economical than rest of the other similar agents currently available in SGLT-2 inhibitors class, which shall help for its better access among middle & low socio-economic strata of the society,” said Sanjay Koul, director of marketing for Mankind Pharma said as per the release.
Remogliflozin etabonate is a sodium glucose co-transporter-2 (SGLT2) inhibitor, a class of drugs that reduce blood glucose by blocking the action of the protein SGLT2 in the kidney.
In April, Glenmark received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. The Mumbai-based pharmaceutical company subsequently launched the drug under the brands ‘Remo’ and ‘Remozen’.
“Our partnership with Mankind is an important milestone in our strategy to widen patients’ access to the latest, novel and globally-researched SGLT2 inhibitor, Remogliflozin in India and will provide a strong foundation for a long-term collaboration with Mankind for Remogliflozin,” said Sujesh Vasudevan, president for India Formulations, Middle East and Africa at Glenmark Pharmaceuticals, was quoted as saying in the release.
Source: Mint